Narcolepsy, Type 2 (Q41285): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed label, description and/or aliases in pt-br, en |
||
| description / pt-br | description / pt-br | ||
Narcolepsia do tipo 2 é um transtorno de sonolência excessiva caracterizado por períodos diários de necessidade incontrolável de dormir ou lapsos diurnos de sono e manifestações anormais do sono REM como demonstrado pelos achados do teste das latências múltiplas do sono (TLMS/PSG) no contexto de sinalização normal da hipocretina hipotalâmica (orexina). Ou seja, as concentração de hipocretina no líquido cefalorraquidiano (LCR) são > 110 picogramas por mililitro. Cataplexia não esta presente. O transtorno não é atribuível a uma doença do sistema nervoso ou outra condição clínica._x000D_ _x000D_ Nota: Um diagnóstico definitivo requer períodos diários de necessidade incontrolável de dormir ou lapsos diurnos para o sono e achados no teste das latências múltiplas do sono/polissonografia (TLMS/PSG) característicos de narcolepsia. Não deve haver evidência de cataplexia ou deficiência de hipocretina no LCR (se o teste for realizado). | |||
| description / en | description / en | ||
Type 2 narcolepsy is a disorder of excessive sleepiness characterised by daily periods of irrepressible need to sleep or daytime lapses into sleep and abnormal manifestations of REM sleep as demonstrated by multiple sleep latency test (MSLT/PSG) findings in the context of normal hypothalamic hypocretin (orexin) signaling. That is, cerebrospinal fluid (CSF) hypocretin determinations are > 110 picograms per milliliter. Cataplexy is not present. The disorder is not attributable to another disease of the nervous system or other medical condition. Note: A definitive diagnosis requires daily periods of irrepressible need to sleep or daytime lapses into sleep and multiple sleep latency test/polysomnography (MSLT/PSG) findings characteristic of narcolepsy. There should be no evidence of cataplexy or CSF hypocretin deficiency (if testing is performed). | |||
Revision as of 07:24, 13 August 2026
Type 2 narcolepsy is a disorder of excessive sleepiness characterised by daily periods of irrepressible need to sleep or daytime lapses into sleep and abnormal manifestations of REM sleep as demonstrated by multiple sleep latency test (MSLT/PSG) findings in the context of normal hypothalamic hypocretin (orexin) signaling. That is, cerebrospinal fluid (CSF) hypocretin determinations are > 110 picograms per milliliter. Cataplexy is not present. The disorder is not attributable to another disease of the nervous system or other medical condition. Note: A definitive diagnosis requires daily periods of irrepressible need to sleep or daytime lapses into sleep and multiple sleep latency test/polysomnography (MSLT/PSG) findings characteristic of narcolepsy. There should be no evidence of cataplexy or CSF hypocretin deficiency (if testing is performed).
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 7A20.1 |
||
| English | Narcolepsy, Type 2 |
Type 2 narcolepsy is a disorder of excessive sleepiness characterised by daily periods of irrepressible need to sleep or daytime lapses into sleep and abnormal manifestations of REM sleep as demonstrated by multiple sleep latency test (MSLT/PSG) findings in the context of normal hypothalamic hypocretin (orexin) signaling. That is, cerebrospinal fluid (CSF) hypocretin determinations are > 110 picograms per milliliter. Cataplexy is not present. The disorder is not attributable to another disease of the nervous system or other medical condition. Note: A definitive diagnosis requires daily periods of irrepressible need to sleep or daytime lapses into sleep and multiple sleep latency test/polysomnography (MSLT/PSG) findings characteristic of narcolepsy. There should be no evidence of cataplexy or CSF hypocretin deficiency (if testing is performed). |
